Clinical trial · Interventional
A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.
A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.
NCT02711345CI-TRIAL-00040707terminatedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): considering the limited clinical activity observed with LTT462, the decision was made to not open the dose expansion phase of the study
Summary
Brief summary (as posted)
A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Non-Small-Cell Lung Carcinoma | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Other Solid Tumors | — | UNRESOLVED | — |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LTT462 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- Escalation
- interventionNames
- Drug: LTT462
- type
- EXPERIMENTAL
- label
- Expansion Group 1
- interventionNames
- Drug: LTT462
- type
- EXPERIMENTAL
- label
- Expansion Group 2
- interventionNames
- Drug: LTT462
- type
- EXPERIMENTAL
- label
- Expansion Group 3
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * Patient (male or female) ≥12 years of age * ECOG (Eastern Cooperative Oncology Group) performance status ≤1 * Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate. * Patients must be willing and able to undergo study required biopsies. * Presence of at least one measurable lesion according to RECIST v1.1. * Documented MAPK pathway alteration Exclusion Criteria: * Prior treatment with ERK inhibitors. * History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. * Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. * Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study. * Patients with malignant disease other than that being treated in the study. * Clinically significant cardiac disease. Other protocol-defined exclusion criteria may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.